You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

AZOPT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Azopt, and when can generic versions of Azopt launch?

Azopt is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in AZOPT is brinzolamide. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the brinzolamide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Azopt

A generic version of AZOPT was approved as brinzolamide by WATSON LABS INC on November 27th, 2020.

  Try a Trial

US Patents and Regulatory Information for AZOPT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz AZOPT brinzolamide SUSPENSION/DROPS;OPHTHALMIC 020816-001 Apr 1, 1998 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AZOPT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sandoz AZOPT brinzolamide SUSPENSION/DROPS;OPHTHALMIC 020816-001 Apr 1, 1998 ⤷  Try a Trial ⤷  Try a Trial
Sandoz AZOPT brinzolamide SUSPENSION/DROPS;OPHTHALMIC 020816-001 Apr 1, 1998 ⤷  Try a Trial ⤷  Try a Trial
Sandoz AZOPT brinzolamide SUSPENSION/DROPS;OPHTHALMIC 020816-001 Apr 1, 1998 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for AZOPT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novartis Europharm Limited Azopt brinzolamide EMEA/H/C/000267
Azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.
Authorised no no no 2000-03-09
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for AZOPT

See the table below for patents covering AZOPT around the world.

Country Patent Number Title Estimated Expiration
Netherlands 300098 ⤷  Try a Trial
Netherlands 300389 ⤷  Try a Trial
South Korea 100196414 ⤷  Try a Trial
Japan 2562394 ⤷  Try a Trial
South Africa 9102580 ⤷  Try a Trial
Australia 7746791 ⤷  Try a Trial
Australia 655924 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AZOPT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0527801 3/2003 Austria ⤷  Try a Trial PRODUCT NAME: BRINZOLAMIDUM; NAT. REGISTRATION NO/DATE: EU/1/00/129/01-02 20000309; FIRST REGISTRATION: LI 55236 19991217
0527801 91555 Luxembourg ⤷  Try a Trial 91555, EXPIRES: 20160403
0527801 SPC/GB03/004 United Kingdom ⤷  Try a Trial PRODUCT NAME: BRINZOLAMIDE; REGISTERED: CH IKS 55236 19991217; UK EU/1/00/129/01 20000309; UK EU/1/00/129/02 20000309
0527801 C300098 Netherlands ⤷  Try a Trial PRODUC NAME: BRINZOLAMIDUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; NATL. REGISTRATION NO/DATE: EU/1/00/129/01-02 20000309; FIRST REGISTRATION: CH IKS 55236 19991217
0527801 CA 2009 00014 Denmark ⤷  Try a Trial
0527801 CA 2002 00030 Denmark ⤷  Try a Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.